ArticleOpen medicine (Warsaw, Poland)2026
Immunohistochemical and bioinformatic analysis of pannexin-1 expression in cutaneous basal and cutaneous squamous cell carcinomas.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: In this two-center study, we aimed to evaluate PANX1 expression in cutaneous squamous cell carcinoma (SCC) and cutaneous basal cell carcinoma (BCC) and to investigate molecular pathways and biological differences associated with PANX1 expression in these tumor types. Methods: In this study, the biopsy samples obtained for pathological examination from patients diagnosed with SCC and BCC were analyzed. The histochemical and immunohistochemical characteristics of the samples were evaluated. Bioinformatics and molecular docking studies were conducted for further analysis. Results: Digital image analysis using immunohistochemical staining and H-score evaluation on paraffin-embedded tissues revealed that PANX1 expression was significantly higher in SCC cases compared to BCC (p<0.001). In SCC, prominent cytoplasmic and membranous staining was observed in invasive tumor foci, while weak and homogeneous staining was detected in BCC samples. Bioinformatic analyses revealed that PANX1 interacts with proteins such as CASP1, CASP3, and P2RX7. However, Venn diagram analysis showed that CASP3 is the only common gene interacting with PANX1 and associated with SCC. No overlap was detected with BCC. Furthermore, molecular docking analyses revealed that ATP binds to PANX1 with high affinity and that caspase-3 establishes a stable interaction near the DVVD cleavage site of PANX1. Conclusions: Our two-center study demonstrated that PANX1 expression is higher in SCC compared to BCC and may play a role in the invasive phenotype. Bioinformatic analyses support the idea that PANX1's interaction with CASP3 through inflammatory and apoptotic pathways may contribute to the progression of SCC. However, more comprehensive studies are needed to determine the diagnostic and prognostic value of PANX1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.